The Latest Breaking News from AstraZeneca

European drugmakers say they are ‘losing ground’ to US and Chinese rivals

Some of continent’s biggest pharma firms write to national leaders calling for action to safeguard the sector

The Guardian - UK · Sep 22

Global Market: European shares rise as oil slide boosts risk appetite

European shares rose as technology stocks led gains and falling oil prices eased inflation concerns. The STOXX 600 advanced 0.56%, while investors also tracked the upcoming Trump-Xi meeting.

The Economic Times · Sep 21

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

The Economic Times · Sep 21

Breast Cancer Drug Wins Accelerated Approval Four Months After FDA Advisers Voted Six to Three Against It

FDA granted camizestrant accelerated approval for ESR1-mutated breast cancer months after its advisory committee voted against the application.

Medical Daily · Sep 9

New Mortality Analysis Puts COPD Above Breast and Prostate Cancer Deaths as Rural Americans Carry Heaviest Burden

New research presented in Barcelona found COPD death rates exceeded those of prostate and breast cancer and matched those of heart failure in a national records study.

Medical Daily · Sep 7

AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant

The trial being halted comes as another blow to the pharmaceutical company

The Independent UK · Aug 17

AstraZeneca ditches lung cancer treatment trial

The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

Evening Standard · Aug 17

FTSE 100 drifts lower in mixed day for Europe

The index closed down 22.56 points, 0.2%, at 10,750.11.

Evening Standard · Aug 14

Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk Knudsen says the company is doubling down on innovation and its weight loss pills as it looks toward its next stage of growth.

Fortune · Aug 6

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders

The Guardian - UK · Aug 5